ABOUT THE 13th ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
Back for its 13th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. The forum also features keynote speeches by KOL and about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event. The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees at the dedicated meeting facilities. We anticipate more than 1700 face-to-face meetings to take place throughout 2 days.
Plenary Sessions will Include:
Global Outlook for Biopharma in 2020
Early Stage Investor Roundtable
Latest Trends in Private Equity and VC
Pharma DealMakers Roundtable
China Partnering & Investment Panel
Rising Stars: Start-Up Showcase
More Sessions TBA shortly...
Therapeutic Panels include:
Advances in C&G Therapies Panel
Autoimmune & Inflammatory Diseases Panel
Neuroscience BD&L Panel
Platform Technologies & Novel Therapeutics Panel
Oncology Advanced Therapies and Diagnostics Panel
Oncology DealMaking Panel
More Panels TBA shortly...
Confirmed Keynotes in 2019 Included:
The Scientific & Investment Potential of Cannabinoids by Jim DeMesa, CEO, Emerald Health Pharmaceuticals
MetrioPharm AG - Considering an IPO: “How to best prepare yourself for this enabling step?” Interview with Dr. Wolfgang Brysch, Founder & CEO, MetrioPharm AG by Dr. Søren Bjønness, Director – Switzerland Representative, Euronext
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.
Presenters at the 12th ELSCEO Forum Included:
Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at 13th Annual European Life Sciences CEO Forum is an effective way to gain leads, introduce new products and services, expand sales, and build relationships. Exhibition space is very limited - express your interest to secure the area.
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on + 44 (0)203 463 4890 or by email: Silvia.
SILVER SPONSORS IN 2019:
SUPPORTED BY IN 2019:
PARTICIPATING PHARMAS IN 2019:
FINANCIAL, ADVISORY, INVESTORS IN 2019: AbbVie Ventures Abingworth LLP ACXIT Capital Management GmbH aescuvest international GmbH Alpha Omega LLC Andera Partners Arix Bioscience Plc. Avego Healthcare Capital Bay City Capital, LLC BB Biotech Ventures BERNINA BioInvest Ltd BioBac BioValley Basel Business Angels Club BioMedPartners AG BioSeed Capital BioStart Consulting GmbH Böhler Life Science